ライフサイエンスコーパス: superiority

1 .35; P<0.001 for noninferiority; P<0.001 for superiority).

2 9; P = 0.01 for noninferiority; P = 0.95 for superiority).

3 detection rates in favour of PSMA (test for superiority).

4 5 to 55; P<0.001 for both noninferiority and superiority).

5 o, 0.54; 95% CI, 0.37 to 0.79; P = 0.001 for superiority).

6 nce interval [CI], 0.78 to 0.91; P<0.001 for superiority).

7 1.00; P<0.001 for noninferiority; P=0.04 for superiority).

8 placebo with respect to efficacy (P=0.06 for superiority).

9 roup (P<0.001 for noninferiority; P=0.85 for superiority).

10 1.36; P=0.006 for noninferiority; P=0.87 for superiority).

11 r superiority; odds ratio, 0.73; P<0.001 for superiority).

12 ty and superiority of relugolix (P<0.001 for superiority).

13 ge points; 95% CI, 10.4 to 23.2; P<0.001 for superiority).

14 , 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority).

15 ; p<0.0001 for non-inferiority, p=0.0051 for superiority).

16 75; P<0.001 for noninferiority; P = 0.01 for superiority).

17 atio, 0.72 [95% CI, 0.55-0.94]; P=0.0150 for superiority).

18 eeding to combine positive alleles for trait superiority.

19 were not powered, and are being assessed for superiority.

20 ddressed the fundamental assumption of tonal superiority.

21 feriority margin, 7.5 percentage points) and superiority.

22 rovement in quality of life through clinical superiority.

23 feriority margin, 7.5 percentage points) and superiority.

24 ority trials, but with many also powered for superiority.

25 ] [2-sided 95% CI, 0.84 to 1.09; P = .50 for superiority]).

26 al [CI], 0.32 to 0.95 [two-tailed P=0.04 for superiority]).

27 .2%, 3.7-59.2; posterior probability of ECMO superiority 0.9861).

28 ninferiority <0.001), but not superiority (p superiority = 0.0465).

29 ] vs 269 [63%], RR 1.18, 95% CI 1.07-1.29; p(superiority)=0.0005) and the hybrid approach was non-inf

30 hybrid approach (66%, RR 1.19, 1.02-1.40; p(superiority)=0.026), compared with clinic-based ART (54%

31 und {UCB} 8.1%]; p(non-inferiority)=0.034, p(superiority)=0.071).

32 6.5 [UCB 5.7%]; p(non-inferiority)=0.0058, p(superiority)=0.50).

33 , -11.9 to 4.0; risk ratio, 0.77; 95% CI for superiority, 0.46 to 1.31).

34 -25.0 to -3.6; risk ratio, 0.69; 95% CI for superiority, 0.51 to 0.92).

35 -1.5; P<0.001; risk ratio, 0.74; 95% CI for superiority, 0.57 to 0.95; P = 0.04).

36 4.3; P = 0.004; risk ratio, 0.98; 95% CI for superiority, 0.62 to 1.55; P = 0.93).

37 to -3.5%, P for noninferiority, <.001; P for superiority, .004).

38 ce between nutrient efficacy and chemotactic superiority accelerates invasion.

39 t toothpaste formulations showed evidence of superiority against placebo or fluorides (amine fluoride

40 lbirth or neonatal death were evaluated with superiority analyses, and possible maternal bacterial in

41 The primary evaluation of efficacy was a superiority analysis in the per-protocol efficacy popula

42 y noninferiority analysis and an exploratory superiority analysis of RIV4 over IIV4.

43 Superiority analysis showed significantly lower use of h

44 Superiority analysis was performed on the secondary outc

45 A superiority analysis was prespecified if noninferiority

46 nd the occurrence of vomiting (assessed in a superiority analysis) within 30 minutes after zinc admin

47 Competitive superiority and high relative fitness of whi2 and psr1ps

48 within 4 weeks after randomization (to show superiority) and COPD-related health status at 2 weeks a

49 1% for DCB versus 83.2% for PTA, P=0.025 for superiority) and the primary patency rate was significan

50 to 0.81; P<0.001 for both noninferiority and superiority), and in 16.1% of the patients receiving asp

51 delay (AVD), contributing to its hemodynamic superiority, and evaluated its applicability for AVD opt

52 atio, 0.72 [95% CI, 0.52-0.98]; P=0.0338 for superiority), as was the primary safety (cardiac death a

53 The main drawbacks and superiorities associated with each array as well as the

54 Results demonstrated SSC's superiority at localizing Wernicke's area.

55 sher exact test was <.001, which crossed the superiority boundary (P = .0061), the data and safety mo

56 ginal prolapse were enrolled in a randomized superiority clinical trial between April 2013 and Februa

57 ug-coated stent free from polymer, has shown superiority compared with a bare-metal stent.

58 H-IMRT failed to demonstrate superiority compared with C-IMRT in long-term disease ou

59 1.8-mg/kg dose of osocimab met criteria for superiority compared with enoxaparin for the primary out

60 se of 1.8 mg/kg of osocimab met criteria for superiority compared with enoxaparin with a risk differe

61 We previously demonstrated the superiority, compared to conventional 4-week passive org

62 ned, a risk-benefit analysis may allow for a superiority comparison and, therefore, avoid setting a n

63 Randomized (1:1), open-label, superiority controlled trial, comparing WOCA prophylaxis

64 Randomized (1:1), open-label, superiority-controlled trial compared WOCA prophylaxis t

65 Superiority could not be concluded for number of episode

66 This superiority coupled with strong quantitative agreement w

67 sion is controversial due to the only modest superiority demonstrated over placebo.

68 ny phase 4 RCTs focused on efficacy (using a superiority design), contemporary phase 4 RCTs often are

69 azine, and prednisone (BEACOPPesc) and INRT (superiority design).

70 d synergizes with antibiotics.METHODSIn this superiority-design study, we randomly assigned 121 patie

71 ts because the posterior probability of ECMO superiority exceeded the prespecified monitoring boundar

72 Superiority for dose escalation was declared if the one-

73 Results from single-centre trials showing superiority for DPPHR were not confirmed in the multicen

74 terim analysis and declared overall survival superiority for nivolumab over investigator's choice the

75 er than 1 (threshold for trial conclusion of superiority >99%).

76 MOFs without compromising their crystalline superiority holds a grand challenge to unveil their pris

77 blood pressure of at least 160 mm Hg with a superiority hypothesis.

78 Here, the synergistic superiorities in both activity and stability of corrugat

79 2D-based nanohybrids have shown unparalleled superiorities in the field of electrochemical biosensors

80 Secondary end points included superiority in achieving biochemical end points (>50% an

81 inical standard, cystatin C (CysC) has shown superiority in assessment of renal function in disease s

82 Paclitaxel exhibits its superiority in drug penetration and accumulation, result

83 l call set comparison demonstrates its clear superiority in finding common indels among call sets.

84 Moreover, RecBic also showed superiority in identifying functionally related genes in

85 Both devices demonstrated superiority in limb revascularization compared with non-

86 um angle of resolution [logMAR] margin), and superiority in mean photopic monocular DCNVA (difference

87 en met the prespecified primary end point of superiority in mean VA gain compared with anti-VEGF mono

88 Moreover, aging-related superiority in perceiving background motion is associate

89 prising 243,732 variants and demonstrate its superiority in removing noisy variants and conducting hy

90 randomized prospective trial failed to show superiority in the 5-year biochemical and/or clinical di

91 Both methods were consistent in showing no superiority in time encoding for low over high frequenci

92 ion-exclusion criteria for trials to aim for superiority in visual outcomes with newer agents.

93 among men (73%, RR 1.34, 95% CI 1.16-1.55; p(superiority)<0.0001) as did the hybrid approach (66%, RR

94 ints were met, with posterior probability of superiority more than 0.999 for both.

95 This randomised, open-label, superiority multicentre, three-arm, parallel group trial

96 UKSTAR was a pragmatic, superiority, multicentre, randomised controlled trial do

97 entage points (rate ratio, 0.60; P<0.001 for superiority; odds ratio, 0.73; P<0.001 for superiority).

98 By integrating the superiorities of hypoxia regulation function, tumor accu

99 In spite of the superiorities of TMUPS, its adoption has been challenged

100 Conclusion: Our study demonstrates the superiority of (18)F-FDG PET over MRI data sets for resp

101 The superiority of (64)Cu-CBP7 was traced to a much higher m

102 riven by the hypothetical degree of clinical superiority of 1-time therapy to repeated intravitreal i

103 Summary ROC curve demonstrated overall superiority of 3-T imaging, with or without intra-articu

104 e architecture lacking Cand1 which indicates superiority of a system with exchange factor if substrat

105 the unblinded phase of the study, indicated superiority of active iTBS on clinician- and self-rated

106 infection model was used to demonstrate the superiority of an apramycin-5-O-glycoside in reducing th

107 This clearly indicates the superiority of AnGDH over other conventionally used fung

108 The evidence reviewed shows no superiority of any single IOL implantation technique in

109 improve survival but do not demonstrate the superiority of any specific antibiotic time or fluid vol

110 The superiority of apixaban over warfarin in regard to effic

111 apy, with particular interest in whether the superiority of beta-lactams links to key cytokine pathwa

112 1 (N = 1,395; median follow-up, 106 months), superiority of bleomycin, etoposide, doxorubicin, cyclop

113 etabolic reconstructions and demonstrate the superiority of BoostGAPFILL to state-of-the-art gap fill

114 ween the two active intervention groups, and superiority of both intervention groups over usual care.

115 rofiban using a noninferiority margin of 9%, superiority of both tirofiban and cangrelor compared wit

116 N: Our findings show no evidence of clinical superiority of brief guided parent-delivered CBT.

117 The superiority of C-prM-E VLPs suggests that inclusion of c

118 tion, numerous studies have demonstrated the superiority of catheter ablation over pharmacological th

119 SPYRAL Pivotal showed the superiority of catheter-based renal denervation compared

120 ved alignment of macro-anatomy validates the superiority of CBA+ compared to CBA.

121 INTERPRETATION: We found no evidence for the superiority of CBT or short-term psychoanalytical therap

122 ratory longitudinal analyses also showed the superiority of CBT over GSH-I by the 6-month (adjusted e

123 The qualitative superiority of CD8(+) T cells retained in hemizygous mic

124 angrelor compared with chewed prasugrel, and superiority of chewed prasugrel as compared with integra

125 primary objective of this study was to show superiority of clinical response at week 48 for guselkum

126 , we found moderate to high evidence for the superiority of combinations of 1 or more Lactobacillus s

127 Our results demonstrate the superiority of COOH-NHMe (IV) in detecting more lipid an

128 Randomized trial data support the superiority of coronary artery bypass grafting (CABG) su

129 ry outcome of 6-month late lumen loss showed superiority of DCB angioplasty over conventional balloon

130 primary effectiveness end point was met, and superiority of DCB over PTA was achieved (83.9% [188 of

131 d of the 95% CI is greater than zero (7.3%), superiority of dolutegravir was also concluded (p<0.0001

132 hile randomized trials have demonstrated the superiority of drug-coated balloon (DCB) angioplasty ver

133 Meanwhile, DeepCode reveals the superiority of epigenomic features and their dominant ro

134 In the absence of evidence of clinical superiority of expensive versus less costly options, sub

135 rative-learning approaches demonstrating the superiority of federated learning, and discuss practical

136 This work therefore exemplifies the superiority of high-entropy materials for the preparatio

137 on that supports the clinical observation of superiority of HMA over cytarabine in this difficult-to-

138 This update aims to confirm and explain the superiority of hyperfractionated radiotherapy over other

139 Randomized trials established the superiority of ibrutinib-based therapy over chemoimmunot

140 us trials (SAMMPRIS and VISSIT) did not show superiority of intracranial stenosis stenting over inten

141 However, superiority of IORAT over the other two procedures shoul

142 Superiority of IVIG to placebo reached statistical signi

143 The results demonstrate no superiority of low frequencies in timing judgments but r

144 nt drug action are sufficient to explain the superiority of many FDA-approved drug combinations in th

145 Cellular assays revealed the superiority of MG-6267 to single-targeted inhibitors of

146 in-stent/scaffold segment at 12 months with superiority of MgBRS over SES in the as-treated populati

147 Here we attempt to explain the superiority of Mo by directly comparing Fe and Mo suppor

148 ase stage, and cytogenetics, with prognostic superiority of MRD negativity versus CR particularly evi

149 Moreover, the superiority of MULTiPly was also validated on a newly co

150 The present review encloses the superiority of nanomaterials from zero to three-dimensio

151 A planned 3-month analysis demonstrated the superiority of netarsudil/latanoprost FDC over its indiv

152 The objective was to validate the superiority of nonlinear imputation of PaO2/FIO2 among m

153 aluate ERCC1 prospectively and to assess the superiority of nonplatinum therapy over platinum doublet

154 Our data suggest no superiority of novel perfusates HTK-N and TiProtec in te

155 secondary analysis was performed to test for superiority of number of injections received up to month

156 Based upon this the authors conclude "the superiority of ocular ultrasound in the diagnostic manag

157 Since the trial was designed to show superiority of once-daily radiotherapy and was not power

158 re no high-quality studies demonstrating the superiority of one anastomotic technique over the other.

159 patients with atrial fibrillation (AF), the superiority of one strategy over another is still questi

160 ional data cannot definitively establish the superiority of one technique over another.

161 We verified the superiority of our design concept by achieving an unprec

162 ue clearing, all of which contributed to the superiority of our method.

163 independent validation dataset, revealed the superiority of our newly proposed integrative approach.

164 There were 14 primary hypotheses: superiority of pembrolizumab alone and of pembrolizumab

165 Our experiments show the superiority of personalized models over their generalize

166 This study highlights the superiority of plasmonic excitation on improving electro

167 We illustrate the superiority of PRAS over existing approaches on predicti

168 Superiority of preperitoneal compared with subcutaneous

169 atients treated in RESONATE, where continued superiority of progression-free survival (PFS) (hazard r

170 he same associated immunosuppressive agents, superiority of PTCY over ATG was confirmed.

171 The debate around the potential superiority of quantum annealers over their classical co

172 Superiority of R-ACVBP over R-CHOP14 was not established

173 or before 24 weeks (two-sided alpha=0.05 for superiority of ranibizumab 0.2 mg against laser therapy)

174 % CI, 4.1 to 11.8) showed noninferiority and superiority of relugolix (P<0.001 for superiority).

175 All other key secondary end points showed superiority of relugolix over leuprolide (P<0.001).

176 for Peripheral Artery Disease) demonstrated superiority of rivaroxaban plus aspirin versus aspirin t

177 The primary endpoint of superiority of secukinumab versus adalimumab for ACR20 r

178 ection (STOP-IT), and results suggest global superiority of short-duration therapy for intra-abdomina

179 risons of sstr antagonists and agonists, the superiority of sstr antagonists was demonstrated in seve

180 s designed to test the 1-sided hypothesis of superiority of tandem transplant compared with single tr

181 f acute ischemic stroke, 1 that demonstrated superiority of tenecteplase and the other that showed no

182 The key secondary end point, powered for superiority of the ACURATE neo bioprosthesis, was new pe

183 AAV8 and other serotypes, we demonstrate the superiority of the approach in a side-by-side comparison

184 perimental and clinical studies indicating a superiority of the closed-loop DBS to open-loop HF DBS,

185 des are obtained, and the analysis shows the superiority of the constructed model.

186 The primary hypothesis was the superiority of the downstream versus the upstream strate

187 rt (n=294; 6-month follow-up), demonstrating superiority of the HM3 for the trial primary end point (

188 Pharmacodynamic studies have suggested superiority of the longer 10-day regimen of decitabine t

189 le size of 1154 patients was needed to prove superiority of the open group.

190 The superiority of the proposed approach for labeling verteb

191 The superiority of the proposed MB separation technique over

192 y analysis of the primary endpoint suggested superiority of the SAPIEN 3 device over the ACURATE neo

193 Decision-curve analysis (DCA) confirmed the superiority of the SORT over other previously published

194 oxygenated counterparts clearly indicate the superiority of the sulfur-based species and emphasize th

195 out the world, the mechanistic basis for the superiority of these drugs is poorly understood.

196 e results of an interim analysis that showed superiority of these groups to ZMapp and remdesivir with

197 eric biologic mesh, little data exist on the superiority of these materials in the setting of high-ri

198 omized clinical trials have demonstrated the superiority of thin-strut biodegradable polymer second-g

199 d (1)O(2) production phenomenon but also the superiority of this next generation of nanoplatforms.

200 and provided computational evidence for the superiority of this substitution pattern to tetra-ortho-

201 The superiority of this technique can open an avenue to esta

202 y, time-to-first-event analysis did not show superiority of ticagrelor monotherapy following one-mont

203 was designed to test a 1-sided hypothesis of superiority of training compared with active control.

204 studies and clinical trials, suggesting the superiority of transendocardial stem cell injection beca

205 erpotential of 96 mV, further confirming the superiority of Tri-Ag-NPs as a catalyst for CO2RR toward

206 Key secondary end points at week 12 were the superiority of upadacitinib over abatacept in the change

207 The superiority on efficacy and safety outcomes of apixaban

208 In this multicentre, parallel group, superiority, open-label, blinded-endpoint, randomised co

209 e most likely mechanism of AR160 therapeutic superiority over ABX or rituximab alone.

210 lar oedema (DMO) are being designed to prove superiority over aflibercept when this agent is already

211 ue to the lack of supporting evidence of its superiority over an open approach and concerns regarding

212 litinib, a JAK 1 and JAK 2 inhibitor, showed superiority over best available therapy in a phase 2 stu

213 sistance, the clinical data supporting their superiority over colistin-based therapy, and the differe

214 CAP's superiority over EUC at the end of treatment was largely

215 HAP's superiority over EUC at the end of treatment was largely

216 rning method for PPI prediction, which shows superiority over existing sequence-based methods.

217 glutamine to glucose rather than glutamine's superiority over glucose in feeding the tricarboxylic ac

218 Pembrolizumab continued to show superiority over ipilimumab after almost 5 years of foll

219 nd impeded migration of tumor cells, showing superiority over isosequential phosphorothioate oligodeo

220 The data show that PAM has superiority over its monovalent counterpart in powering

221 The envisaged method has superiority over others in terms of its operational simp

222 Lisdexamfetamine demonstrated superiority over placebo on the log-rank test (chi21, 40

223 completer samples, GSK561679 failed to show superiority over placebo on the primary outcome of chang

224 indicating short-term (ie 16-week treatment) superiority over placebo.

225 analyses of AZA and CSA indicated short-term superiority over placebo; however, nonvalidated scores w

226 mation from DNA methylation data, and showed superiority over the other three methods in imputation e

227 [ 0.53-2.11], noninferiority P value=0.006, superiority P value=0.867), although an increase in myoc

228 meeting the noninferiority criterion but not superiority (P = .76).

229 feriority (p noninferiority <0.001), but not superiority (p superiority = 0.0465).

230 e results of 2 pivotal trials that confirmed superiority (PARTNER [Placement of Aortic Transcatheter

231 We did this superiority, placebo-controlled randomised trial in 19 f

232 DESIGN, SETTING, AND PARTICIPANTS: Superiority, placebo-controlled randomized clinical tria

233 gy met prespecified criteria for statistical superiority, precluding definitive conclusions.

234 In this multicentre, pragmatic, three-arm, superiority randomised trial, patients referred to secon

235 4; P < .001 for noninferiority; P < .001 for superiority; rate difference, -130.31 episodes per 100 P

236 3; P < .001 for noninferiority; P < .001 for superiority; rate difference, -61.94 episodes per 100 PY

237 (modified intention to treat [mITT] for the superiority safety analysis and mITT and per protocol fo

238 The fighting and courtship superiority seen in ES males could reinforce fitness and

239 ble-blind, single-centre, placebo-controlled superiority study (ISRCTN12562026, funded by Cultech Ltd

240 erver-blinded, active-comparator-controlled, superiority study in 200 community-resident adults aged

241 In this randomised, controlled, open-label, superiority study, we recruited hospitalised adults aged

242 ; less than 10(-4)) at EOCT (62% v 13%) with superiority sustained through month 24 (end of therapy).

243 specified margin of 6 percentage points) and superiority testing were performed in the as-treated pop

244 art approaches developed for this problem, a superiority that is reflected particularly in the absolu

245 In this pragmatic, superiority, three-arm, individually randomised, single-

246 ption of thiazide or thiazide-like diuretics superiority to angiotensin-converting enzyme inhibitors

247 not shown, with paclitaxel plus ART showing superiority to both oral etoposide plus ART and bleomyci

248 arsudil/latanoprost FDC met the criteria for superiority to each active component at all 9 time point

249 ver, there is scarce evidence to support its superiority to high-definition white-light endoscopy.

250 ized controlled trials (RCTs), demonstrating superiority to placebo or relevant control treatments, a

251 f neutralizing antibodies, demonstrating its superiority to vaccines adjuvanted by monophosphoryl lip

252 matic, observer-blind, randomised controlled superiority trial (IMPACT) at 15 National Health Service

253 did a double-blind, randomised, controlled, superiority trial at one rural site in Uganda with high

254 fficacy demonstrated with non-inferiority or superiority trial designs according to existing regulato

255 testing that culminate in a large randomized superiority trial has historically been predominant in o

256 pragmatic, multicenter, randomized clinical superiority trial in 10 intensive care units (ICUs) at 1

257 This open-label, randomised, phase 2, superiority trial in 15 university hospitals in Denmark,

258 ntre, analyst-blinded, randomised controlled superiority trial in 22 clinics in England (UK).

259 rial was an open-label randomised controlled superiority trial in 288 adults recruited April 2014 to

260 n open-label, three-arm, cluster-randomised, superiority trial in Sumba (low malaria transmission sit

261 In this phase 3, open-label, superiority trial in Uganda, we randomly assigned neonat

262 multicentre, open-label, two-arm, randomised superiority trial included adults (aged 16 years or olde

263 unblinded, multicenter, randomized clinical superiority trial involving 30 Dutch hospitals participa

264 ingle-blind, randomised, controlled, phase 2 superiority trial of adult patients with low-risk or Int

265 ragmatic, multicentre, randomised controlled superiority trial of people with progressive multiple sc

266 The study design was a superiority trial of PROSTVAC (Arm V or Arm VG) versus A

267 ternational, open-label, randomised, phase 3 superiority trial that enrolled women aged 18 years or o

268 d, controlled, double-blind, parallel-group, superiority trial was done in 18 hospitals across Europe

269 A multicentre, randomised, open-label, superiority trial was done in eight academic hospitals a

270 center patient-blinded randomized controlled superiority trial was performed in 14 centers between Ap

271 d single-blind cluster-randomized controlled superiority trial was performed.

272 multicentre, randomised, placebo-controlled superiority trial with four parallel groups at 13 memory

273 In this superiority trial with two-sided significance testing, w

274 el, adaptive, randomised controlled, phase 3 superiority trial, participants were recruited from 107

275 In this phase 3 randomised controlled superiority trial, we included general surgery adult inp

276 label, assessor-blinded, randomized clinical superiority trial, with recruitment from October 2012 to

277 , open-label, phase 3, randomised controlled superiority trial.

278 ntre, randomized, controlled, parallel-group superiority trial.

279 ized, prospective, double-masked, controlled superiority trial.

280 8 is an open-label, prospective, randomized, superiority trial.

281 trial was an open-label, phase 3, randomised superiority trial.

282 The use of non-inferiority and superiority trials, and selection of appropriate and opt

283 trial was powered for HbA(1c) and bodyweight superiority under reasonable assumptions.

284 ab did not meet statistical significance for superiority versus adalimumab in the primary endpoint of

285 e to week 26 in bodyweight (oral semaglutide superiority vs placebo and liraglutide).

286 line to week 26 in HbA(1c) (oral semaglutide superiority vs placebo and non-inferiority [margin: 0.4%

287 acebo and non-inferiority [margin: 0.4%] and superiority vs subcutaneous liraglutide) and the confirm

288 This multidimensional superiority was confirmed in a follow-up analysis in the

289 Superiority was defined as the posterior probability of

290 The primary safety end point was met, and superiority was demonstrated; freedom from a primary saf

291 Superiority was determined by a 15% difference in the pr

292 a PASI 75 response at both weeks 12 and 48), superiority was not established (p=0.0616).

293 A test for superiority was planned if rivaroxaban proved to be noni

294 usted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27)

295 Non-inferiority (delta=10%) followed by superiority were tested in the intention-to-treat popula

296 capture the complex mixed feelings of proud superiority when "looking down upon" and acting harshly

297 s claimed noninferiority, of which 20 showed superiority, whereas 23 (21.1%) did not show noninferior

298 Superiority with a low-dose DCB for femoropopliteal inte

299 ne, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in or

300 0.97; P<0.001 for noninferiority, P=0.02 for superiority) with no statistical evidence of heterogenei